Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC., Bieber T., Alten R., Witte T., Galloway J., Deberdt W., Issa M., Haladyj E., De La Torre I., Grond S., Wollenberg A.